You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 24, 2024

Investigational Drug Information for Tirabrutinib

✉ Email this page to a colleague

« Back to Dashboard

What is the drug development status for Tirabrutinib?

Tirabrutinib is an investigational drug.

There have been 9 clinical trials for Tirabrutinib. The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2021.

The most common disease conditions in clinical trials are Leukemia, Lymphoid, Leukemia, Lymphocytic, Chronic, B-Cell, and Leukemia. The leading clinical trial sponsors are Gilead Sciences, Ono Pharmaceutical Co. Ltd, and German CLL Study Group.

There are forty-one US patents protecting this investigational drug and four hundred and seventy-one international patents.

Recent Clinical Trials for Tirabrutinib
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)Ono Pharmaceutical Co. LtdPhase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of Tirabrutinib in Participants With Antihistamine-Resistant Chronic Spontaneous UrticariaGilead SciencesPhase 2
Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's SyndromeGalapagos NVPhase 2

See all Tirabrutinib clinical trials

Clinical Trial Summary for Tirabrutinib

Top disease conditions for Tirabrutinib
Top clinical trial sponsors for Tirabrutinib

See all Tirabrutinib clinical trials

US Patents for Tirabrutinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Tirabrutinib ⤷  Sign Up Phosphatidylinositol 3-kinase inhibitors Gilead Sciences, Inc. (Foster City, CA) ⤷  Sign Up
Tirabrutinib ⤷  Sign Up Prophylactic agent and/or therapeutic agent for diffuse large B-cell lymphoma ONO PHARMACEUTICAL CO., LTD. (Osaka, JP) ⤷  Sign Up
Tirabrutinib ⤷  Sign Up Phosphatidylinositol 3-kinase inhibitors Gilead Sciences, Inc. (Foster City, CA) ⤷  Sign Up
Tirabrutinib ⤷  Sign Up Phosphatidylinositol 3-kinase inhibitors Gilead Sciences, Inc. (Foster City, CA) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Tirabrutinib

Drugname Country Document Number Estimated Expiration Related US Patent
Tirabrutinib Argentina AR100809 2034-06-13 ⤷  Sign Up
Tirabrutinib Australia AU2015274635 2034-06-13 ⤷  Sign Up
Tirabrutinib Brazil BR112016028818 2034-06-13 ⤷  Sign Up
Tirabrutinib Canada CA2952037 2034-06-13 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.